{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:36:28Z","timestamp":1790890588647,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T00:00:00Z","timestamp":1227657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s12185-008-0166-4","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T16:00:16Z","timestamp":1227715216000},"page":"483-488","source":"Crossref","is-referenced-by-count":45,"title":["Advanced mast cell disease: an Italian Hematological Multicenter experience"],"prefix":"10.1007","volume":"88","author":[{"given":"Livio","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina Giovanna","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Caira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Rondoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Van Lint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Allione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marbello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Caramatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Maria","family":"Pogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Iannitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorina","family":"Giona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicetto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosangela","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Fanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Fianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Sanpaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro Maria","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,11,26]]},"reference":[{"key":"166_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","volume":"122","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122:695\u2013717. doi: 10.1046\/j.1365-2141.2003.04575.x .","journal-title":"Br J Haematol"},{"key":"166_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","volume":"25","author":"HP Horny","year":"2001","unstructured":"Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria and immunohistochemical findings. Leuk Res. 2001;25:543\u201351. doi: 10.1016\/S0145-2126(01)00021-2 .","journal-title":"Leuk Res"},{"key":"166_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603\u201325. doi: 10.1016\/S0145-2126(01)00038-8 .","journal-title":"Leuk Res"},{"key":"166_CR4","doi-asserted-by":"crossref","unstructured":"Valent P, Metcalfe DD. Mast cells proliferative disorders: diagnosis, classification and therapy. In: O\u2019Brien S, Teffery A, Valent P, editors. Chronic myelogenous leukemia and myeloproliferative disease. Hematology (Am Soc Hematol Educ Program) 2004; p. 146\u201362.","DOI":"10.1182\/asheducation-2004.1.146"},{"issue":"1","key":"166_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000085561","volume":"114","author":"A Pardanani","year":"2005","unstructured":"Pardanani A. Systemic mastocytosis: bone marrow pathology, classification and current therapies. Acta Haematol. 2005;114(1):41\u201351. doi: 10.1159\/000085561 .","journal-title":"Acta Haematol"},{"key":"166_CR6","unstructured":"Valent P, Horny HP, Li Cy, et al. Mastocytosis (mast cell disease). In: Jaffe ES, Harris NL, Stein H, Vardman J, editors. World Health Organization (WHO) classification of tumors. Pathology and genetics. Tumors of haematopoietic and lymphoid tissue. Vol. 1; 2001. p. 291\u2013302."},{"issue":"5","key":"166_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0889-8588(03)00089-3","volume":"17","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003;17(5):1227\u201341. doi: 10.1016\/S0889-8588(03)00089-3 .","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"166_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14\u201322. doi: 10.1038\/sj.leu.2404955 .","journal-title":"Leukemia"},{"issue":"1","key":"166_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3324\/haematol.12324","volume":"93","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Verstovsek S, Pardanani A. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica. 2008;93(1):6\u20139. doi: 10.3324\/haematol.12324 .","journal-title":"Haematologica"},{"key":"166_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","volume":"27","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635\u201341. doi: 10.1016\/S0145-2126(02)00168-6 .","journal-title":"Leuk Res"},{"key":"166_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ajh.20211","volume":"77","author":"B Hennessy","year":"2004","unstructured":"Hennessy B, Giles F, Cortes J, et al. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol. 2004;77:209\u201314. doi: 10.1002\/ajh.20211 .","journal-title":"Am J Hematol"},{"key":"166_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","volume":"119","author":"P Casassus","year":"2002","unstructured":"Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-\u03b1: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090\u20137. doi: 10.1046\/j.1365-2141.2002.03944.x .","journal-title":"Br J Haematol"},{"issue":"2","key":"166_CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5858\/2005-129-219-EOMCIM","volume":"129","author":"CH Dunphy","year":"2005","unstructured":"Dunphy CH. Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes. Arch Pathol Lab Med. 2005;129(2):219\u201322.","journal-title":"Arch Pathol Lab Med"},{"key":"166_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","volume":"28","author":"AW Hauswirth","year":"2004","unstructured":"Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2004;28:249\u201357. doi: 10.1016\/S0145-2126(03)00259-5 .","journal-title":"Leuk Res"},{"issue":"5","key":"166_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.patbio.2004.04.012","volume":"52","author":"J Simon","year":"2004","unstructured":"Simon J, Lortholary O, Caillat-Vigneront N, et al. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris). 2004;52(5):294\u20139. doi: 10.1016\/j.patbio.2004.04.012 .","journal-title":"Pathol Biol (Paris)"},{"issue":"3","key":"166_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.leukres.2003.09.004","volume":"28","author":"A Tefferi","year":"2004","unstructured":"Tefferi A. Treatment of systemic mast cell disease: beyond interferon. Leuk Res. 2004;28(3):223\u20134. doi: 10.1016\/j.leukres.2003.09.004 .","journal-title":"Leuk Res"},{"issue":"4","key":"166_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJM200101253440415","volume":"344","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344(4):307\u20139. doi: 10.1056\/NEJM200101253440415 .","journal-title":"N Engl J Med"},{"key":"166_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","volume":"28","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res. 2004;28:127\u201331. doi: 10.1016\/S0145-2126(03)00185-1 .","journal-title":"Leuk Res"},{"issue":"13","key":"166_CR19","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270\u20136. doi: 10.1182\/blood-2003-05-1699 .","journal-title":"Blood"},{"key":"166_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","volume":"31","author":"C Akin","year":"2003","unstructured":"Akin C, Brockow K, D\u2019Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild type or mutated forms of c-kit. Exp Hematol. 2003;31:686\u201392. doi: 10.1016\/S0301-472X(03)00112-7 .","journal-title":"Exp Hematol"},{"issue":"7","key":"166_CR21","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/cncr.22187","volume":"107","author":"A Quintanas-Cardama","year":"2006","unstructured":"Quintanas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarijan H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006;107(7):1429\u201339. doi: 10.1002\/cncr.22187 .","journal-title":"Cancer"},{"issue":"Suppl 1","key":"166_CR22","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.leukres.2003.10.003","volume":"28","author":"GW Krystal","year":"2004","unstructured":"Krystal GW. Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leuk Res. 2004;28(Suppl 1):S53\u20139. doi: 10.1016\/j.leukres.2003.10.003 .","journal-title":"Leuk Res"},{"issue":"9383","key":"166_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","volume":"362","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362(9383):535\u20136. doi: 10.1016\/S0140-6736(03)14115-3 .","journal-title":"Lancet"},{"issue":"2","key":"166_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.21996","volume":"7","author":"HJ Droogendijk","year":"2006","unstructured":"Droogendijk HJ, Kluin-Nelemans HJC, van Doormaal JJ, Oranjie AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006;7(2):345\u201351. doi: 10.1002\/cncr.21996 .","journal-title":"Cancer"},{"issue":"5","key":"166_CR25","first-page":"413","volume":"8","author":"D Rossov-Jessen","year":"1991","unstructured":"Rossov-Jessen D, Lovgreen Nielsen P, Horn T. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant. 1991;8(5):413\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"166_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","volume":"37","author":"R Nakamura","year":"2006","unstructured":"Nakamura R, Chakrabarti S, Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant. 2006;37(4):353\u20138. doi: 10.1038\/sj.bmt.1705245 .","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"166_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/sj.bmt.1704627","volume":"34","author":"A Spyridonidis","year":"2004","unstructured":"Spyridonidis A, Thomas AK, Bertz H, et al. Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34(6):515\u20139. doi: 10.1038\/sj.bmt.1704627 .","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"166_CR28","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.leukres.2006.04.005","volume":"30","author":"S Verstovsek","year":"2006","unstructured":"Verstovsek S, Akim C, Manshouri T, et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res. 2006;30(11):1365\u201370. doi: 10.1016\/j.leukres.2006.04.005 .","journal-title":"Leuk Res"},{"issue":"2","key":"166_CR29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107(2):752\u20139. doi: 10.1182\/blood-2005-07-3022 .","journal-title":"Blood"},{"issue":"1","key":"166_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286\u201391. doi: 10.1182\/blood-2005-10-3969 .","journal-title":"Blood"},{"issue":"5","key":"166_CR31","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","volume":"80","author":"D Purtill","year":"2008","unstructured":"Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol. 2008;80(5):456\u20138. doi: 10.1111\/j.1600-0609.2008.01048.x .","journal-title":"Eur J Haematol"},{"key":"166_CR32","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Ayalew T, Jorge C, et al. Phase II study of Dasatinib (SPRYCELTM) in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Abstract no. 3551, ASH 2007.","DOI":"10.1182\/blood.V110.11.3551.3551"},{"key":"166_CR33","doi-asserted-by":"crossref","unstructured":"Rondoni M, Paolini S, Colarossi S, et al. Response to Dasatinib in patients with aggressive systemic mastocytosis with D816V Kit mutation. Abstract no. 3562, ASH 2007.","DOI":"10.1182\/blood.V110.11.3562.3562"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0166-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-008-0166-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0166-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0166-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T08:15:33Z","timestamp":1632384933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-008-0166-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,26]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["166"],"URL":"https:\/\/doi.org\/10.1007\/s12185-008-0166-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,26]]}}}